TrialSignal
Clinical trial intelligence report
A Prospective, Randomized, Controlled Study on Self-monitoring of Blood Glucose (SMBG) Protocols in Predicting Glucose Levels in Senior Patients With Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 24, 2026
Report code
NCT01954771-Jun 24, 2026
NCT ID
NCT01954771
Status
COMPLETED
Phase
Completed
Sponsor
Beijing Anzhen Hospital
Executive brief
Investment-Ready Snapshot
The study conducted by Beijing Anzhen Hospital aimed to optimize SMBG protocols for elderly patients with T2DM and CAD, a demographic that represents a significant and growing segment of the diabetes market. The findings could enhance patient management strategies, potentially leading to improved health outcomes and reduced healthcare costs. The competitive landscape includes established SMBG and CGMS device manufacturers, necessitating a focus on differentiation through enhanced efficacy and patient adherence. Diligence should consider the regulatory environment and reimbursement pathways for diabetes management technologies.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01954771
Indication
Diabetes Mellitus, Type 2
Modality
behavioral intervention
Target
Self-monitoring of blood glucose (SMBG) protocols and continuous glucose monitoring (CGMS) systems for managing glycemic control in senior patients with Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD).
Intervention
SMBG, CGMS
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.